Comparison of the Performance of Five Different Scoring Systems in Patients with ST-Elevation Myocardial Infarction

Comparison of the Performance of Five Different Scoring Systems in Patients with ST-Elevation Myocardial Infarction

Introduction: Although most of the scoring systems are used for long-term mortality assessment in STelevation myocardial infarction (STEMI), there is still lack of data comparing model performances. In this study, it was aimed to compare five scoring systems for predicting long-term mortality in patients presented with STEMI. Patients and Methods: This is a retrospective observational study consisting of 1689 consecutive STEMI patients who underwent PCI between 2009 and 2013. Patient data was obtained from the electronic data base of the hospital. Each patients’ mortality risk was assessed with five different risk scores and recorded. Results: A total of 1689 patients with STEMI were included into the study. Median follow-up time was one year. Risk scores were calculated for each patient. Although similar statistical significance was presented among all scores, modified age, creatinine clearance, and ejection fraction score (mACEF) were demonstrated to be more significant than relevant scoring systems in clinical respect. Conclusion: Among five scores, the mACEF score was demonstrated to be the most significant model in clinical respect for the prediction of mortality.

___

  • 1. Schiele F, Hochadel M, Tubaro M, Meneveau N, Wojakowski W, Gierlotka M, et al. Reperfusion strategy in Europe: Temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction. Eur Heart J 2010;31(21):2614-24.
  • 2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018;39(2):79-82.
  • 3. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, Lemos JA de, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-7.
  • 4. Kozieradzka A, Kamiński KA, Maciorkowska D, Olszewska M, Dobrzycki S, Nowak K, et al. GRACE, TIMI, Zwolle and CADILLAC risk scores-do they predict 5-year outcomes after ST-elevation myocardial infarction treated invasively? Int J Cardiol 2011;148:70-5.
  • 5. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001;286:1356-9.
  • 6. Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB, et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol 2004;93:629-32.
  • 7. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction. The CADILLAC risk score. J Am Coll Cardiol 2005;45:1397-405.
  • 8. Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: An InTIME II sub-study. Lancet 2001;358(9293):1571-5.
  • 9. Wykrzykowska JJ, Garg S, Onuma Y, de Vries T, Goedhart D, Morel MA, et al. Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the ‘All-Comers’ LEADERS trial. Circ Cardiovasc Interv 2011;4:47-56.
  • 10. Littnerova S, Kala P, Jarkovsky J, Kubkova L, Prymusova K, Kubena P, et al. GRACE score among six risk scoring systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, Zwolle) demonstrated the best predictive value for prediction of long-term mortality in patients with ST-elevation myocardial infarction. PLoS One 2015;10(4):e0123215.
  • 11. Kao YT, Hsieh YC, Hsu CY, Huang CY, Hsieh MH, Lin YK, et al. Comparison of the TIMI, GRACE, PAMI and CADILLAC risk scores for prediction of long-term cardiovascular outcomes in Taiwanese diabetic patients with ST-segment elevation myocardial infarction: From the registry of the Taiwan Society of Cardiology. PLoS One 2020;15(2):e0229186.
  • 12. Lev EI, Kornowski R, Vaknin-Assa H, Porter A, Teplitsky I, Ben-Dor I, et al. Comparison of the predictive value of four different risk scores for outcomes of patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2008;102:6-11.
  • 13. Thygesen K, Alpert JS, White HD. Task force members, ESC Committee for practice guidelines, document reviewers, universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. Eur Heart J 2007;28(20):2525-38.
  • 14. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967;20(4):457-64.
  • 15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7(2):79-108.
  • 16. Blanc B, Finch CA, Hallberg L, Herbert V, Lawkowicz W, Layrisse M. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 1968:1-40.
  • 17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41.
  • 18. Van de Werf F, Ardissino D, Betrui A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients with ST-segment elevation. Eur Heart J 2003;24:28-66.
  • 19. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. Task force on the management of ST-elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC guidelines for management of acute myocardial infarction in patientspresenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
  • 20. Windecker S, Hernández-Antolín RA, Stefanini GG, Wijns W, Zamorano JL. Management of ST-elevation myocardial infarction according to European and American guidelines. EuroIntervention 2014;10:23-31.
  • 21. Schellings DA, Adiyaman A, Giannitsis E, Hamm C, Suryapranata H, Ten Berg JM, et al. Early discharge after primary percutaneous coronary intervention: The added value of N-terminal pro-brain natriuretic peptide to the Zwolle Risk Score. J Am Heart Assoc 2014;3:e001089.
  • 22. Raposeiras-Roubín S, Abu-Assi E, Cabanas-Grandío P, Agra-Bermejo RM, Gestal-Romarí S, Pereira-López E, et al. Walking beyond the GRACE (Global Registry of Acute Coronary Events) model in the death risk stratification during hospitalization in patients with acute coronary syndrome: What do the AR-G [ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry and GWTG (Get With the Guidelines) Database], NCDR (National Cardiovascular Data Registry), and EuroHeart Risk Scores Provide? JACC Cardiovasc Interv 2012;5:1117-25.
  • 23. Brkovic V, Dobric M, Beleslin B, Giga V, Vukcevic V, Stojkovic S, et al. Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute STsegment elevation myocardial infarction treated by primary percutaneous coronary intervention. Int J Cardiovasc Imaging 2013;29:1215-28.
  • 24. Méndez-Eirín E, Flores-Ríos X, García-López F, Pérez-Pérez AJ, Estévez-Loureiro R, Piñón-Esteban P, et al. Comparison of the prognostic predictive value of the TIMI, PAMI, CADILLAC, and GRACE risk scores in STEACS undergoing primary or rescue PCI. Rev Esp Cardiol 2012;65:227-33.
  • 25. Chan Pin Yin D, Azzahhafi J, James S. Risk assessment using risk scores in patients with acute coronary syndrome. J Clin Med 2020;9(9):3039.
  • 26. González-Pacheco H, Arias-Mendoza A, Álvarez-Sangabriel A, JuárezHerrera Ú, Damas F, Eid-Lidt G, et al. The TIMI risk score for STEMI predicts in-hospital mortality and adverse events in patients without cardiogenic shock undergoing primary angioplasty. Arch Cardiol Mex 2012;82(1):7-13.
  • 27. Huang J, Wei X, Wang Y, Jiang M, Lin Y, Su Z, et al. Comparison of prognostic value among 4 risk scores in patients with acute coronary syndrome: Findings from the improving care for cardiovascular disease in China-ACS (CCC-ACS) Project. Med Sci Monit 2021;27:e928863.
  • 28. Halkin A, Stone GW, Dixon SR. Impact, and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. Am J Cardiol 2005;96:325-31.
  • 29. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, et al. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 2004;44:547-53.
Koşuyolu Heart Journal-Cover
  • ISSN: 2149-2972
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 1990
  • Yayıncı: Sağlık Bilimleri Üniversitesi, Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi